Harnessing regulatory T cells to establish immune tolerance.

Ho, Patrick; Cahir-McFarland, Ellen; Fontenot, Jason D; Lodie, Tracey; Nada, Adel; Tang, Qizhi; Turka, Laurence A; Bluestone, Jeffrey A

Ho, Patrick; Cahir-McFarland, Ellen; Fontenot, Jason D; Lodie, Tracey; Nada, Adel; Tang, Qizhi; Turka, Laurence A; Bluestone, Jeffrey A.

Afiliación

Ho P; Diabetes Center, University of California San Francisco, San Francisco, CA 94143, USA.
Cahir-McFarland E; Abata Therapeutics, Boston, MA 02472, USA.
Fontenot JD; Sangamo Therapeutics, Brisbane, CA 94005, USA.
Lodie T; Quell Therapeutics, London W12 OBZ, UK.
Nada A; GentiBio, Cambridge, MA 02140, USA.
Tang Q; Diabetes Center, University of California San Francisco, San Francisco, CA 94143, USA.
Turka LA; Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA.
Bluestone JA; Gladstone Institute of Genomic Immunology, University of California San Francisco, San Francisco, CA 94143, USA.

Sci Transl Med ; 16(738): eadm8859, 2024 Mar 13.

Article en En | MEDLINE | ID: mdl-38478632

ABSTRACT

ABSTRACT

Engineered regulatory T (Treg) cells have emerged as precision therapeutics aimed at inducing immune tolerance while reducing the risks associated with generalized immunosuppression. This Viewpoint highlights the opportunities and challenges for engineered Treg cell therapies in treating autoimmune and other inflammatory diseases.

Asunto(s)

Enfermedades Autoinmunes; Linfocitos T Reguladores; Humanos; Tolerancia Inmunológica; Terapia de Inmunosupresión

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Autoinmunes / Linfocitos T Reguladores Límite: Humans Idioma: En Revista: Sci Transl Med Asunto de la revista: CIENCIA / MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google